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Abstracts
Background: To investigate the Cochleo-vestibular clinical and audiometric findings in Multi and Extreme Drug
Resistance(MDR and XDR) tuberculosis(TB) patients on treatment and make recommendations.
Methods: A cross-sectional study of adult MDR and XDR-TB patients was conducted in a general hospital in Cape-
Town-South-Africa. Ethical approval was secured and all consenting patients administered with pretested and
validated questionnaire under the guidance of International Classification of Functioning, Disability and Health(ICF)
Checklist-version-2.1a. Audiometric evaluation included: Otoscopy, Diagnostic Audiometry and Tympanometry. The
data analyses were done with SPSS version 16, Chi-square and StatCalc-7.
Results: Fifty-three adults, ages 18-60 (mean-33 years) comprising 26 males and 27 females participated in the
study. Hospital stay duration varied from 1-18 months (mean-6 months) and all were on anti-Koch’s second line
drugs (regimen 2). MDR TB group were 45(85%) and XDR 8(15%). Vertigo was the most common vestibular
symptoms, 24(45%) whereas, tinnitus 23(42%) and hearing loss 13(25%) were most frequent auditory complaints.
Bilateral sensorineural hearing losses of varying degrees were confirmed in 23(47%).
There was no association between gender and age with hearing loss [c
2 (P = 0.16, ά = 0.05) and (p = 0.13, ά =
0.05)]. Furthermore, MDR and XTR TB groups [20/42 Vs 3/8; Z = 0.46 and P = 0.64], showed no difference in pattern
of the hearing losses.
Conclusions: A multi-disciplinary close surveillance of MDR and XDR TB patients on therapy is imperative. Finally,
researches into therapeutic trials on antidotes and potent safer substitutes for aminoglycosides in the management
are recommended.
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Introduction
Following the advent of HIV-AIDS in 1981 there has
been the explosion of opportunistic infections and glo-
bal resurgence of diseases, prominent among which is
tuberculosis (TB). The control of this disease especially
in the developing world has suffered a great set back fol-
lowing resistance to conventional regimen for treatment
of TB. As a result, the prevalence of multidrug-resistant
(MDR) and extensively drug-resistant (XDR) tuberculo-
sis particularly in Africa has been on the rise. Meyer
and McAdam in 2007, reported an alarming rate of
about to 1000/1000 000 TB infections including the
resistant strains in the Western Cape Province of South
Africa [1].
In South Africa, TB patients typically undergo treat-
ment with first line TB treatment (regimen 1) drugs:
Rifampicin, isoniazid (INH), pyrazinamide, and etham-
butol [2]. MDR TB is resistance to at least two main
first-line TB drugs (Isoniazid and Rifampicin) and XDR
t ot h r e eo rm o r eo ft h es i xc l a s s e so fs e c o n d - l i n ed r u g s
respectively [3]. To this end, patients are left with the
option of management with extreme drugs like Amika-
cin, streptomycin belonging to the aminoglycosides, che-
motherapeutic agents with potential ototoxicity and
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worse than the initial symptoms. Absolute loss of hear-
ing loss, tinnitus, and vertiginous spells are among com-
mon cochlea-vestibular disorders that could arise from
the treatment. This poses a huge potential threat to the
eradication of the MDR and XDR TB since side effects
could promote low compliance and high attrition rate to
treatment.
Therefore, there is need for monitoring of the patients
by health personnel during the course of management
to curtail the side effects and encourage compliance to
treatment.
It is following this that we conducted a survey among
the in-patients undergoing MDR and XDR TB treatment
in a general hospital in the province of Western Cape of
South Africa to ascertain their spectrum of otovestibular
clinical symptoms and audiometric profiles. It is hoped
that this will act as a guide to the physicians involved in
the management of this disease.
Materials and methods
This was a cross sectional study involving adult patients
(ages 18-60 years) on ward admission diagnosed and
currently under treatment for MDR or XDR TB. The
drugs were administered by Specialist Medical team at
right dose and durations. Volunteers who were within
this age range and on admission for treatment lasting at
least 2 weeks were consecutively selected into this sur-
vey. The essence of the closed age selection was to
ensure validity of consent (at least age 18) and to limit
the effect of presbycusis (beyond age 60 years). Mini-
mum period of admission of 2 weeks was to ensure
enough compliance and exposure of patients to the
drugs. Patients with evidence suggestive of hearing loss
prior to the commencement of therapy were excluded
from the study.
Consent
Prior to the commencement of the study, ethical
approval was obtained from the Human Research Ethic
Committee of the Faculty of Health Sciences of the Uni-
v e r s i t yo fC a p eT o w n .I na d dition, permission to con-
duct the research was also granted by the hospital
management of the participating hospital and the Wes-
tern Cape Provincial Department of Health. Call for par-
ticipants were sourced and respondents were asked to
indicate their willingness to take part in this study
through the endorsement of consent forms.
Instrument and data collection
Major instrument used for this work was a self devel-
oped questionnaire under the guidance of International
Classification of Functioning, Disability and Health
(ICF) - Checklist version 2.1a. Inputs were also made by
4 clinical audiologists with at least 5 years of experience
(see Additional file 1). The questionnaire comprises
three key sections: Demographic information, Impair-
ment of Body Functions, and Activities limitations &
Participation restrictions. The questionnaire was pre-
tested on 12 patients in the same institution prior to the
commencement of the study. The outcome of the pre-
test was used for validation of the questions. Subse-
quently, a survey was conducted using the self adminis-
tered and pre-tested/validated questionnaires.
Following the administration of the questionnaire,
audiometric evaluations were conducted for the patients
via otoscopy using Heine Mini 2000 Otoscope (to elimi-
nate wax impaction and pre-existing auditory canal and
tympanic membrane defects), GSI-38 screening tympa-
nometry was also used (to rule out middle ear disorders)
and Pure Tone Audiometry with model GSI 61 diagnos-
tic audiometer in a standard sound proof boot(to ascer-
tain the degree and type of hearing loss).
Data analysis
The SPSS version 16, Chi-square and StatCalc-7 were
used for data entrance, cleaning and analysis.
Results
Fifty-three adults, ages 18-60 (mean 33 years) compris-
ing 26 males and 27 females took part in the study.
Their length of hospital stays varied from 1- 18 months
(mean: 6 months). They were all on anti-koch’ss e c o n d
line drugs treatment (i.e. regimen 2). Those on Multi-
Drug Resistant (MDR) TB treatment were 45 (85%) and
extensively drug-resistant (XDR) TB 8(15%). No pre-
vious established history of hearing loss prior to enrol-
ment into the therapy was established from any of the
participants, however; 15(29%) had history of noise
exposure in previous jobs but no evidence of resultant
hearing loss
Figure 1, below illustrates the various vestibular disor-
ders reported by the participants and the various
degrees of severity. Among these, Vertigo; nausea and
vomiting were most common and were recorded in 24
(45%) and 21(40%) respectively, of the participants.
Tinnitus 23(42%) was the most frequently reported
auditory complaint reported by the participants. Hearing
loss of different degrees was the second most common
13(25%), out of which 21% reported severe hearing
losses in high frequencies. The frequency of distribution
and reported severity of other auditory symptoms were
as illustrated in Figure 2 below.
Objective audiological assessment was completed in 49
(92%), 4 had a clash with their time for medication and
could not complete the investigations. From the afore-
mentioned 23(47%) had objective confirmed bilateral
hearing losses of varying degrees (mild to profound) as
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Page 2 of 5Figure 1 Most frequently reported vestibular-balance problems. The common vestibular-balance problems reported by the participants
(n = 53) and the severity were shown above; with Vertigo/Nausea and vomitting as most frequent.
Figure 2 Frequent auditory complaints reported by the participants (n = 53). Tinnitus and hearing loss were most preponderant auditory
features recorded. It is worthy of note that the total % here is 110% because the symptoms are not mutually exclusive and therefore some
occur in combinations.
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subjectively from patients (Figure 2).
Statistical calculations using Z-test 2 sample showed
no statistical difference in the frequency of hearing
losses recorded among the MDR and XTR TB groups
20/42 Vs 3/8; Z = 0.46 and P = 0.64. This suggests that
the drug rather than the severity of disease was main
determinant of level of hearing loss.
Further analysis of the results using inferential statis-
tics (Chi-square, c
2) revealed no association between the
gender of the participant and hearing loss (PTA) (P =
0.16, ά = 0.05). There was also no significant correlation
between the age of the participants and the degree of
hearing loss (p = 0.13, ά = 0.05).
Discussions
The side effects emanating from the amino glycosides
used in the MDR and XTR appears a potential threat to
the successful management of this recalcitrant illness.
The above findings of 42% cases of tinnitus and 25%
reporting hearing losses among the in-patients, who
were supposedly under the surveillance of the physician
is rather a major health issue. The audiometric findings
even revealed a higher proportion (47%) of patients with
significant hearing losses. This report is in consonance
with the findings of Torun et al [4] via a retrospective
study conducted in Turkey where Ototoxicity from
MDR-TB therapy yielded 41.8%. Other reports include
de Jagger et al [5], in a 14 day case controlled study car-
ried out among patients on prolonged therapy of amino-
glycosides for TB therapy in the Netherlands 18%;
Schacht [6], 10-20% in acute infection therapy and more
in tuberculosis.
Various reports from different parts of the world have
shown wide variations in the incidence of ototoxicity
b u tt h ef a c tr e m a i n st h a ti ti sag l o b a lp r o b l e m .H o w -
ever, these variations could be explained following the
presence of inherent modifiers such as genetic predispo-
sition to aminoglycoside. Growing evidence has shown
that mitochondrial 125rRNA gene mutations leading to
12S rRNA A1555G were under lying factors to
aminoglycoside ototoxicity susceptibility particularly in
Asian populations [7] Many families were found to
transmit the aminoglycoside gene via matrilineal inheri-
tance. The mitochondrial ribosome of the cochlear hair
cells are believed to be the target attacked by the amino
glycosides leading to processing of abnormal DNA or
interference in the translation process culminating in an
irreversible auditory malfunction [7,8].
A recent research finding has suggested that this
genetic predisposition could be a significant factor
among the South Africans [9] A genetic study carried
out by the above worker and team, mapped genes
A1555G and A827G among the Black race and Afrika-
ners of South Africa respectively, thus making them sus-
ceptible to aminoglycoside ototoxicity. This may justify
the high incidence of oto-toxicity recorded in our study
since the drugs were administered in the correct dosage
by the managing physicians.
It is worthy of note that there was no significant cor-
relation between sex, age or severity of illness (MDR or
XDR TB) and ototoxicity pattern in this study. This is
in agreement with an earlier study by de Jagger, et al [5]
and strongly suggests that the ototoxic effect solely
arises from the therapy. In addition there was no statis-
tical correlation between the period of therapy and
severity of hearing loss/other auditory symptomatolo-
gies. Thus, a little exposure could lead to severe audi-
tory dysfunctions depending on individuals’ genetic
make-up. This is why it might be very difficult to define
a generally acceptable duration for treatment of MDR
and XDR TB patients.
Quite significant number of respondents reported ves-
tibular symptoms other than nausea and vomiting. Ver-
tigo (45%) and other related spatial disorders such as
sensation of falling (40%) appear to be prominent fea-
tures of the vestibulotoxicity from the anti MDR, TDR
drugs. In a related report by WHO TB control sites,
14.8% had prominent vestibular symptoms against 12%
hearing losses [10] although this is contrary to our
report whereby the percentage hearing losses were
more, however; it emphasises the importance of balance
disturbances. Most often, less attention is paid to the
vestibulotoxic symptoms of the ototoxic agents used in
the Resistant TB therapy. However; the adverse compli-
cations following severe vestibular disturbances like falls
and fractures (especially among the elderly), psychiatric
disturbances, increase suicidal tendencies and generally
poor quality of life are well documented [11-14]
Limitations of the study
It would have been ideal to perform objective pre and
post treatment audiological studies on all the patients
using Ultra high frequency audiometry; the latter moni-
tors frequencies above 8 kHz which aminoglycoside
Table 1 Audiometric data for the participants (n = 49)
Degree of Hearing loss (dB HL) N Percentage
Normal (PTA: -10 to 25) 26 53%
Mild (PTA: 26 to 40) 7 14.5%
Moderate (PTA: 41 to 55) 7 14.5%
Moderately severe (PTA: 56 to 70) 3 3%
Severe (PTA: above 71) 6 12%
Total 49 100
*ALL participants had bilateral Sensorineural Hearing Loss of varying degrees
as shown in the table. The frequencies of hearing losses were mainly beyond
4000 kz.
PTA–Pure Tone Audiogram; dB HL–Decibel Hearing Loss
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concentrations for aminoglycosides through-out the
course of treatment to regulate and also determine toxic
levels would have been desirable; however the logistics
for the research work did not support these.
Conclusions
From the above findings it is pertinent that physicians
and health care givers need to do more than present. A
multi disciplinary surveillance of the patients diagnosed
for MDR and XDR prior, during and after the comple-
tion of recommended regimen is imperative.
Again we posit that, such patients require monitoring
of serum concentrations for aminoglycosides; genetic
screening when possible, for the rRNA and related
defective genes for aminoglycoside ototoxicity prior to
commencement of therapy. This will aid informed con-
sent and guarded treatment. During the course of ther-
apy, monitoring should go beyond ward admission; the
Audiologist, Otolaryngologist, Nephrologists and Hepa-
t o l o g i s t ss h o u l db ei n v o l v e dt oe n s u r et h ep r o t e c t i o n
and rehabilitation of vulnerable organs.
Finally, a permanent solution appears to lie on ability
to discover a safer and effective chemotherapy for the
treatment of MDR and XDR TB. Therefore, Pharmacol-
ogists and Chemists must increase their experimental
takes toward finding an alternative and complete repla-
cement for aminoglycosides in this respect.
Additional material
Additional file 1: Contains the proforma and some essential
questions represented in the questionnaiore administered to all
patients.
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